Windtree Therapeutics Files 8-K on Security Holder Vote Matters

TL;DR

Windtree Therapeutics (WINT) is holding a shareholder vote on Feb 3rd.

AI Summary

On February 3, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware, is involved in biological products and is headquartered in Warrington, Pennsylvania.

Why It Matters

This filing indicates that Windtree Therapeutics is engaging its security holders in important corporate decisions, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: low — The filing is a routine procedural report regarding a vote of security holders and does not disclose any new material financial or operational risks.

Key Numbers

• 001-39290 — SEC File Number (Identifies the company's filing history with the SEC.)
• 94-3171943 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Windtree Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Warrington, Pennsylvania (location) — Principal executive offices
• February 3, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma

Filing Documents

• wint20250203_8k.htm (8-K) — 34KB
• 0001437749-25-002624.txt ( ) — 163KB
• wint-20250203.xsd (EX-101.SCH) — 3KB
• wint-20250203_def.xml (EX-101.DEF) — 11KB
• wint-20250203_lab.xml (EX-101.LAB) — 15KB
• wint-20250203_pre.xml (EX-101.PRE) — 11KB
• wint20250203_8k_htm.xml (XML) — 3KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. On February 3, 2025, Windtree Therapeutics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") virtually. As of December 20, 2024, the record date for the Special Meeting, there were 11,048,828 outstanding shares of the Company's common stock. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Special Meeting, which are described in the Company's Definitive Proxy Statement on Schedule 14A for the Special Meeting, filed with the U.S. Securities and Exchange Commission on January 8, 2025. (a) Proposal 1 - Approval of an amendment to the Company ' s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company ' s outstanding shares of common stock by a ratio of any whole number between 1-for-5 and 1-for-50, the implementation and timing of which shall be subject to the discretion of the Company ' s Board of Directors (the " Board " ). The votes with respect to the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's outstanding shares of common stock by a ratio of any whole number between 1-for-5 and 1-for-50, the implementation and timing of which shall be subject to the discretion of the Board, were as follows: Votes For Votes Against Abstentions Broker Non-Votes 2,504,535 1,752,258 103,627 0 (b) Proposal 2 - Approval of an amendment to the Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan (the " A&R 2020 Plan " ) to increase the number of shares of common stock authorized for issuance under the A&R 2020 Plan from 41,010 shares to 1,141,010 shares. The votes with respect to the approval of an amendment to A&R 2020 Plan to increase the number of shares of common stock authorized for is

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: February 3, 2025

View Full Filing

View this 8-K filing on SEC EDGAR